Appendix cancer differential diagnosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
'''For the WikiDoc page for this topic, click [[Appendix cancer|here]]'''
'''For the WikiDoc page for this topic, click [[Appendix cancer|here]]'''


Line 15: Line 16:
{| class="wikitable"
{| class="wikitable"
|-  
|-  
! colspan="2" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;"|Diseases
! colspan="2" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases
| colspan="7" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations'''
| colspan="7" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations'''
! colspan="7" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings
! colspan="7" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings
| colspan="1" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard'''
|-
|-
| colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms'''
| colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms'''
Line 98: Line 98:
* CK 19
* CK 19
* CK 20
* CK 20
| style="background: #F5F5F5; padding: 5px;" |[[Biopsy]]
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Carcinoid tumor<sup>2</sup>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Carcinoid tumor<sup>2</sup>
Line 144: Line 142:


'''IHC''' might be positive for '''S100'''
'''IHC''' might be positive for '''S100'''
| style="background: #F5F5F5; padding: 5px;" | [[Biopsy]]
|-
|-
| style="background: #DCDCDC; padding: 5px;" |Goblet cell carcinoid
| style="background: #DCDCDC; padding: 5px;" |Goblet cell carcinoid
Line 189: Line 185:
::*Nuclear pleomorphism  
::*Nuclear pleomorphism  
::*Increased mitotic activity
::*Increased mitotic activity
| style="background: #F5F5F5; padding: 5px;" |[[Biopsy]]
|-  
|-  
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;"|Diseases
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Abdominal pain'''
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Abdominal pain'''
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Change in girdle size
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Change in girdle size
Line 206: Line 201:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other diagnostic studies and imaging modalities
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other diagnostic studies and imaging modalities
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology
| style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard'''
|-
|-
| rowspan="4" style="background: #DCDCDC; padding: 5px; text-align: center;" |Appendix Mucocele
| rowspan="4" style="background: #DCDCDC; padding: 5px; text-align: center;" |Appendix Mucocele
Line 243: Line 237:
| rowspan="4" style="background: #F5F5F5; padding: 5px;" |N/A
| rowspan="4" style="background: #F5F5F5; padding: 5px;" |N/A
| style="background: #F5F5F5; padding: 5px;" |Similar to hyperplastic colon polyp
| style="background: #F5F5F5; padding: 5px;" |Similar to hyperplastic colon polyp
| style="background: #F5F5F5; padding: 5px;" |[[Biopsy]]
|-
|-
| style="background: #DCDCDC; padding: 5px;" |Simple or retention cyst
| style="background: #DCDCDC; padding: 5px;" |Simple or retention cyst
Line 255: Line 248:
| style="background: #F5F5F5; padding: 5px;" |N/A
| style="background: #F5F5F5; padding: 5px;" |N/A
| style="background: #F5F5F5; padding: 5px;" |Degenerative epithelial changes because of obstruction
| style="background: #F5F5F5; padding: 5px;" |Degenerative epithelial changes because of obstruction
| style="background: #F5F5F5; padding: 5px;" | Biopsy
|-
|-
| style="background: #DCDCDC; padding: 5px;" | Mucinous cystadenomas
| style="background: #DCDCDC; padding: 5px;" | Mucinous cystadenomas
Line 277: Line 269:
* Histologically benign
* Histologically benign
* Similar to colon adenomatous polyps or villous adnomas
* Similar to colon adenomatous polyps or villous adnomas
| style="background: #F5F5F5; padding: 5px;" |Biopsy
|-
|-
| style="background: #DCDCDC; padding: 5px;" |  Mucinous cystadenocarcinomas
| style="background: #DCDCDC; padding: 5px;" |  Mucinous cystadenocarcinomas
Line 294: Line 285:
* Glandular invasion into the stoma
* Glandular invasion into the stoma
* Pseudomyxoma peritonei
* Pseudomyxoma peritonei
| style="background: #F5F5F5; padding: 5px;" |[[Biopsy]]
|-  
|-  
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;"|Diseases
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Abdominal pain'''
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Abdominal pain'''
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Change in girdle size
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Change in girdle size
Line 311: Line 301:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other diagnostic studies and imaging modalities
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other diagnostic studies and imaging modalities
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology
| style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard'''
|-
|-
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" | [[Ovarian cancer differential diagnosis|Ovarian cancer]]
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" | [[Ovarian cancer differential diagnosis|Ovarian cancer]]
Line 370: Line 359:
| style="background: #F5F5F5; padding: 5px;" | N/A
| style="background: #F5F5F5; padding: 5px;" | N/A
| style="background: #F5F5F5; padding: 5px;" | Depends on the tumor type. You may find the details [[Ovarian cancer differential diagnosis|here]].
| style="background: #F5F5F5; padding: 5px;" | Depends on the tumor type. You may find the details [[Ovarian cancer differential diagnosis|here]].
| style="background: #F5F5F5; padding: 5px;" |[[Biopsy]]
|-
|-
| colspan="2" style="background: #DCDCDC; padding: 5px;" |[[Colorectal cancer]]
| colspan="2" style="background: #DCDCDC; padding: 5px;" |[[Colorectal cancer]]
Line 419: Line 407:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Depends on the tumor type.. You will find more information [[Colorectal cancer differential diagnosis|here]]
* Depends on the tumor type.. You will find more information [[Colorectal cancer differential diagnosis|here]]
| style="background: #F5F5F5; padding: 5px;" |[[Biopsy]]
|-
|-
| colspan="2" style="background: #DCDCDC; padding: 5px;" |[[Pseudomyxoma peritonei differential diagnosis|Pseudomyxoma peritonei]]
| colspan="2" style="background: #DCDCDC; padding: 5px;" |[[Pseudomyxoma peritonei differential diagnosis|Pseudomyxoma peritonei]]
Line 457: Line 444:
*:* [[MUC2]]
*:* [[MUC2]]
*:* MUC5AC
*:* MUC5AC
| style="background: #F5F5F5; padding: 5px;" |
* Diagnostic laparascopy/laparatomy
|-
|-
| colspan="2" style="background: #DCDCDC; padding: 5px;" |[[Carcinoid syndrome]]
| colspan="2" style="background: #DCDCDC; padding: 5px;" |[[Carcinoid syndrome]]
Line 514: Line 499:
** CD56 and PGP ( less specific)
** CD56 and PGP ( less specific)
** PDX1 and ISL1
** PDX1 and ISL1
| style="background: #F5F5F5; padding: 5px;" |[[Biopsy]] from the tumor is the gold standard method of diagnosis, meanwhile
5-HIAA (5-hydroxyindoleacetic acid) is the most specific marker of carcinoid tumors
|-
|-
| colspan="2" style="background: #DCDCDC; padding: 5px;" |[[Appendicitis differential diagnosis|Appendicitis]] <sup>3</sup>
| colspan="2" style="background: #DCDCDC; padding: 5px;" |[[Appendicitis differential diagnosis|Appendicitis]] <sup>3</sup>
Line 557: Line 539:
| style="background: #F5F5F5; padding: 5px;" |[[Tc-99m]] labeled anti-[[CD15]] [[antibodies]]  
| style="background: #F5F5F5; padding: 5px;" |[[Tc-99m]] labeled anti-[[CD15]] [[antibodies]]  
| style="background: #F5F5F5; padding: 5px;" |Evidences of [[inflammation]]
| style="background: #F5F5F5; padding: 5px;" |Evidences of [[inflammation]]
| style="background: #F5F5F5; padding: 5px;" |A combination of Imaging (ultrasonography or CT scan, while CT scan is more sensitive), physical exam and history
[[Appendicitis diagnostic scoring|Alvarado Score]]
|-  
|-  
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;"|Diseases
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Abdominal pain'''
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Abdominal pain'''
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Change in girdle size
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Change in girdle size
Line 575: Line 555:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other diagnostic studies and imaging modalities
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other diagnostic studies and imaging modalities
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology
| style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard'''
|}
|}



Revision as of 17:00, 18 February 2019


For the WikiDoc page for this topic, click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]

Overview

Appendix cancer must be differentiated from benign appendix lesions (mucocele, acute appendicitis), colorectal cancers, adenexal masses (ovarian tumors), and carcinoid tumors of the other organs.

Differentiating appendix cancer from other Diseases

  • Appendix cancer must be differentiated from benign appendix lesions (mucocele, acute appendicitis), colorectal cancers, adenexal masses (ovarian tumors), and carcinoid tumors of the other organs.
  • As appendix cancer manifests in a variety of clinical forms, differentiation must be established in accordance with the particular subtype.
  • Carcinoid tumors must be differentiated from other diseases that causecarcinoid syndrome, such as palpitation, facial flushing, diarrhea, .
  • In contrast, adenocarcinomas and cystadenocarcinomas must be differentiated from other diseases that cause acute appendicitis or present with pseudomyxoma peritonei, such as colorectal cancers, appendix mucoceles.
Diseases Clinical manifestations Para-clinical findings
Symptoms Physical examination
Lab Findings Imaging Histopathology
Abdominal pain Change in girdle size Change in bowel habits Other symptoms Abdominal mass abdominal tenderness Other physical examination findings Urinary 5-hydroxyindoleacetic acid (5-HIAA) and/or Serum Chromogranin A (CgA) Other lab findings CT scan MRI Utrasounography Other diagnostic studies and imaging modalities
Appendix cancer Adenocarcinoma1 +/- -/+ Constipation
  • Generally asymptomatic
  • Appendicitis symptoms
  • Nausea & vomiting,decreased appetite (anorexia)
  • No gas or stool pass (intestinal obstruction)
  • Bone pain (bone metastasis)
  • Bloating (ascites)
- - -
  • CEA
  • CA 19-9
  • Soft tissue thickening
  • Wall irregularity
  • Presence of pseudomyxoma peritonei
  • Calcification
  • Internal septations
  • Periappendiceal fat stranding and intraperitoneal free fluid which is a nonspecific finding
  • Cystic lesion
  • Diffusion weighted MRI has been shown to be the modality of choice for peritoneal carcinomatosis
  • Increased fluid signal on T2 weighted sequence
  • Soft tissue mass in the appendix
  • Invasion to other structures
  • Dilated appendix
  • Periappendiceal fluid collection
  • Distinct appendix wall layers
Positron emission tomography (PET) Gross pathology:
  • Gray/yellow color
  • Cystic structures with angiolymphatic invasion
  • Appendix might be buried within the mass

Microscopic pathology:

  • Intestinal, mucinous or signet ring cell types
  • Coexisting acute appendicitis is common

IHC might be positive for the following stains:

  • MUC 2
  • MUC5AC
  • CK 8/18
  • CK 13
  • CK 19
  • CK 20
Carcinoid tumor2 +/- - Diarrhea
  • Generally asymptomatic
  • Flushing
  • Palpitation
  • Dyspnea
- -
  • Tricuspid regurgitation
  • murmur
  • Wheezing
+
  • Ki67: a reliable marker of cell proliferation
Gross pathology:
    • Prevalent at the tip of appendix
    • Generally less than 1 cm
    • Gray or yellow
    • Well-demarcated firm
    • Intramural nodules that may narrow or obliterate appendiceal lumen
    • Proximal tumors may cause obstruction and appendicitis

Microscopic pathology:

  • Insular growth pattern of solid islands of uniform polygonal cells with minimal pleomorphism
  • Retraction of peripheral tumor cells from stroma
  • Angiolymphatic invasion is common
  • Granular eosinophilic cytoplasm with either diffusely scattered or peripherally clumped granules
  • Two types of well differentiated tumors: EC cell (serotonin producing) and rarely L-cell (enteroglucagon or peptide YY producing)

IHC might be positive for S100

Goblet cell carcinoid + +/- + +/- +
  • Ascites
  • Shifting dullness
  • May appear anemic
+/-
  • CK 20
  • CK 7
  • Synapthosin
  • pancreatic polypeptide
  • CEA
  • CA 19-9
  • CA 125
Unfortunately, compared to the other carcinoid tumors of appendix, GCC is more aggressive and patients with GCC generally present at higher stages. Hence, in addition to the above mentioned general findings for appendix cancers, imaging studies should look for evidences of peritoneal involvement, bone metastasis, lymphadenopathy, and metastatic lesions in ovaries and/or prostate.

Gross pathology:

  • No gross tumor might be present
  • Thickened appendiceal wall

Microscopic appearance:

  • GCC Generally spares mucosa and infiltrates muscularis propria and periappendiceal fat
  • Tumor cell clusters
  • Crypt-like structures
  • Tubules of mucus-secreting cells distended with mucin resembling goblet cells
  • Eosinophilic cytoplasm resembling carcinoid tumors
  • Pools of extracellular mucin
  • Scattered Paneth cells in tumors with crypt like structures
  • Extensive perineural invasion
  • Carcinomatous growth pattern:
  • Cribriform growth pattern, solid sheets of infiltrating signet ring cells
  • Nuclear pleomorphism
  • Increased mitotic activity
Diseases Abdominal pain Change in girdle size Change in bowel habits Other symptoms Abdominal mass Abdominal tenderness Other physical examination findings Urinary 5-hydroxyindoleacetic acid (5-HIAA) and/or Serum Chromogranin A (CgA) Other lab findings CT scan MRI Utrasounography Other diagnostic studies and imaging modalities Histopathology
Appendix Mucocele Mucosal hyperlasia - - -
  • Generally asymptomatic
  • Benign even after rupture
- +/- N/A - N/A
  • low attenuation well defined mass in RLQ near cecum
  • Inflammation is the key to distinguish between appendicitis and mucocele
  • Wall thickness does not distinguish between malignant and benign mucocele
  • Intramural nodule is a sign of neoplastic lesions
  • Imaging is not a reliable method to distinguish between neoplastic and nonneoplastic lesions, hence every patient should undergo surgery, appendectomy and histopathologic evaluation of the lesion
|Rounded right iliac fossa mass
  • T1: the signal depends on the mucin concentration, may be from hypointense to isointense
  • T2: hyperintense
N/A Similar to hyperplastic colon polyp
Simple or retention cyst - - - - +/- - - N/A Degenerative epithelial changes because of obstruction
Mucinous cystadenomas +/- +/- +/-Diarrhea

+/-Constipation

  • Generally asymptomatic
  • Rupture may lead to Pseudomyxoma peritonei
+/- +/- If develop pseudomyxoma peritonei: -
  • CEA
  • CA 19-9
  • Histologically benign
  • Similar to colon adenomatous polyps or villous adnomas
Mucinous cystadenocarcinomas +/- +/- +/-Diarrhea

+/-Constipation

+/- +/- - -
  • CEA
  • CA 19-9
  • Glandular invasion into the stoma
  • Pseudomyxoma peritonei
Diseases Abdominal pain Change in girdle size Change in bowel habits Other symptoms Abdominal mass Abdominal tenderness Other physical examination findings Urinary 5-hydroxyindoleacetic acid (5-HIAA) and/or Serum Chromogranin A (CgA) Other lab findings CT scan MRI Utrasounography Other diagnostic studies and imaging modalities Histopathology
Ovarian cancer +/- +/- +/-Constipation
  • Pelvic/abdominal pain or pressure
  • Vaginal bleeding/discharge
  • Dyspnea
  • GI disturbance
+ +/-
  • Ascites
  • Shifting dullness
  • Fever
  • Pleural effusion
-
  • Depends on the underlying etiology
  • Iron
  • HCG
  • LDH
  • Calcium
  • Estrogen
  • progestron
  • Testosterone
  • AFP
  • CA 125
  • Ki 67
  • Adnexal mass
  • Adenexal Cyst (simple or complex)
  • Fluid accumulation
  • Endometrial thickening
  • calcification
  • Pleural effusion
  • Peritoneal involvement
  • Lymphandenopathy
  • Adnexal mass
  • Adenexal Cyst (simple or complex)
  • Except for Thecoma, ovarian masses are generally hyperintense on T1 and hypo or isointense on T2 imaging
  • Fluid accumulation
  • Endometrial thickening
  • calcification
  • Pleural effusion
  • Peritoneal involvement
  • Lymphandenopathy
  • Adnexal mass
  • Adenexal Cyst (simple or complex)
  • Fluid accumulation
  • Increased Doppler flow
  • Endometrial thickening
  • calcification
N/A Depends on the tumor type. You may find the details here.
Colorectal cancer +/- +/- +/-Diarrhea

+ Constipation

+ +/- Colonoscopy

Adenocarcinoma

Carcinoids

-/+(Carcinoid tumors) luminal narrowing, intestinal wall thickening,intussusception, bowel obstruction, hepatic metastases, intestinal perforation,enlarged lymph nodes
  • Tumor mass and the extension of tumor to other structures
Generally not recommended: may evaluate liver metastasis or presence of fluid in abdominal cavity, but it is neither sensitive nor specific. PET scan, Endoscopy, Colonoscopy,

Barium enema

  • Depends on the tumor type.. You will find more information here
Pseudomyxoma peritonei + + +/-Diarrhea

+/-Constipation

Bloating - + Ascites

Shifting dullness

-
  • Non specific
  • Depends on the etiology of the disease
  • Low-attenuation
  • Scalloping of the visceral surfaces differentiates pseudomyxoma from other causes of peritnoitis.
  • Typically does not invade visceral organs or spread by lymphatic or hematogenous routes unlike mucinous carcinomatosis

Characterized by a mass which is hypointense on T1-weighted MRI and hyperintense on T2-weighted MRI. MRI has better sensitivity in detecting ascites fluid and mucocele.

  • The echoes within pseudomyxoma peritonei are not mobile.
  • Echogenic septations within the gelatinous ascites.
  • Scalloping of the hepatic and splenic margins
18F-FDG PET scan
  • Depending on WHOclassification, whether it's low or high grade with cellular atypia or acellular mucin. ( DPAM, PMCA)
  • Gelatinous ascites in peritoneum and visceralorgans,usually underneath the right hemidiaphragm, liver.
  • Omental cake
    • Immunohistochemisty
Carcinoid syndrome -/+ - Diarrhea Flushing

Palpitation

Dyspnea

- -
  • Tricuspid regurgitation
  • murmur
  • Wheezing
+ Depends on the tumor type: Depends on the primary tumor location and type Depends on the primary tumor location and type Depends on the primary tumor location and type
  • Salt and pepper nuclei
  • Cellular uniformity
  • Central ovoid nucleus
  • Presence of ribbons, trabeculae, nesting, glands, gyriform, pseudorosettes
  • Insulinoma (Amyloid deposition)
  • Somatostatinom (Psammoma bodies)
  • Hyaline globules
  • IHC
    • Synaptophysin (almost always, strongly and diffusely expressed )
    • Chromogranin A
    • CD56 and PGP ( less specific)
    • PDX1 and ISL1
Appendicitis 3 Periumbelical, RLQ - +/- Diarrhea
  • Intermittent
  • Secretory type

+ Constipation

Nausea & vomiting,decreased appetite

Anorexia

+/- + - Appendiceal wall thickening /perforation

peri-appendiceal inflammation, fluid accumulation,fat stranding

Increased fluid signal on T2 weighted sequence Evidences of inflammation
  • Dilated appendix
  • Periappendiceal fluid collection
  • Distinct appendix wall layers
Tc-99m labeled anti-CD15 antibodies Evidences of inflammation
Diseases Abdominal pain Change in girdle size Change in bowel habits Other symptoms Abdominal mass Abdominal tenderness Other physical examination findings Urinary 5-hydroxyindoleacetic acid (5-HIAA) and/or Serum Chromogranin A (CgA) Other lab findings CT scan MRI Utrasounography Other diagnostic studies and imaging modalities Histopathology

1 Adenocarcinomas usually present with appendicitis, barely they might present with Pseudomyxoma peritonei; meanwhile Pseudomyxoma peritonei is more prevalent in perforated mucocele, goblet cell tumor or high stages of adenocarcinoma.

2 Generally appendix carcinoids are asymptomatic, they were only become symptomatic if they metastasize to the liver, or in rare cases make an obstruction and present with appendicitis which is quit uncommon in appendiceal carcinoids compared to appendiceal adenocarcinoma. Any patient with carcinoid syndrome should be evaluated for appendix carcinoids.

3 Every patient with appendicitis should be evaluated for appendix cancer, 0.5 in 100 appendicitis cases are because of appendix cancer.

*Abbreviations: RLQ: Right Lower Quadrant, AFP:Alpha Fetoprotein, HCG: Human chorionic gonadotropin, LDH: Lactate Dehydrogenase, CEA: Carcinoembryonic antigen, CA 125: Cancer antigen 125

References